Highest-materiality recent filing
Equity plan amended to increase authorized shares by 500,000 to 3,175,000; approved with 994,315 votes for.
TAO Synergies raises $11M in private placement; terminates Alkon agreement; appoints Vice-Chairman
Sold 11,000 Series E convertible preferred shares ($1,000 stated value) and warrants for 1.375M common shares at $8.00; $11M gross proceeds.
Joseph Jacks, co-founder/CEO of Latent Holdings and early Bittensor pioneer, engaged as advisor to digital asset treasury strategy led by James Altucher.
TAOX shareholders approve 20%+ share issuance and 2M-share equity plan increase
Special meeting held Aug 6, 2025; 567,847 shares (35.23%) represented, quorum achieved.
TAO Synergies accumulates 42,111 Bittensor (TAO) tokens as part of DeAI treasury strategy
As of Aug 5, 2025, holds 42,111 TAO tokens acquired via purchases and staking.
TAO Synergies acquires $10M in TAO tokens, becoming largest public pure play holder
Acquired 29,899 TAO tokens for $10M at avg ~$334/token as of July 17, 2025.
Synaptogenix rebrands to TAO Synergies, shifts to AI-focused crypto treasury with staking
Name changed to TAO Synergies Inc. effective June 26, 2025; ticker to change from SNPX to TAOX on July 1.
Synaptogenix buys TAO, hires BitGo for custody/staking, begins staking yield
Initial purchase of TAO under crypto treasury strategy focused on AI and machine learning.
Synaptogenix launches crypto treasury strategy focused on Bittensor TAO, raises $5.5M
Plans initial $10M acquisition of TAO tokens (over 2x market cap); long-term target of $100M.
Synaptogenix forms special committee to explore strategic alternatives; ends Bryostatin-1 MS trial
Board formed special committee to explore strategic opportunities; $19.6M cash and ~1.3M shares outstanding as of Sept 30, 2024.
Synaptogenix replaces auditor: Morison Cogen resigns, Stephano Slack engaged for FY2024
Morison Cogen resigned Sept 30, 2024 due to exit from public company audit services.
Synaptogenix raises $5M via Series C Convertible Preferred and warrants
Closed private placement of Series C Preferred (convertible at $4/share) and warrants for aggregate gross proceeds of $5M.
Gross proceeds of $5.0M from sale of 5,000 shares of Series C convertible preferred stock (stated value $1,000) and warrants.
Synaptogenix effects 1-for-25 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse split effective 5pm ET April 4, 2024; shares trade split-adjusted on April 5 under SNPX.
Stockholders authorized reverse stock split at ratio between 1:8 and 1:25, at Board's discretion.
Synaptogenix invests up to ~$3.44M in Cannasoul Analytics for preferred shares and convertible notes
Initial investment: $562,770 for 12,737 Series A preferred shares (5% stake) at $44.1550/share.
Synaptogenix partners with Cleveland Clinic for Phase 1 Bryostatin-1 trial in multiple sclerosis
Agreement with Cleveland Clinic to conduct Phase 1 trial of Bryostatin-1 in multiple sclerosis; IND submission to FDA planned.
Synaptogenix receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified Synaptogenix on April 24, 2023 that its stock failed to maintain minimum $1.00 closing bid price for 30 consecutive days.
Synaptogenix Phase 2 trial of Bryostatin-1 fails to meet primary endpoint in advanced Alzheimer's
Primary endpoint: change in SIB total score at week 28; Bryostatin-1 1.4 pts vs placebo 0.6 pts, not statistically significant.
Synaptogenix creates Series B Convertible Preferred, closes $15M private placement
Issued Series B Convertible Preferred Stock with initial conversion price of $7.75 per share.
Gross proceeds of $15M from sale of Series B convertible preferred stock (initial conversion at $7.75/share) and warrants.
On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.
On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee
On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.
On September 30, 2021, George Perry resigned from his position as a member of the board of directors (the “Board”) of Synaptogenix, Inc. (the “Company”) and as a member of all committees of the Board on which he serves.
Max materiality 0.90 · Median 0.60 · Most common event other_material